|
|
The Diabetes Market Outlook: Market Analysis Of Future Growth And Leading Players By SectorPublished by: Business Insights Published: Jan. 1, 2005 - 156 Pages Table of ContentsTable of Contents The Diabetes Market Outlook: Market analysis of future growth and leading players by sector Executive summary 12 Epidemiology analysis 12 Global diabetes market analysis 13 Insulin market analysis 14 Oral antidiabetic (OAD) market analysis 15 Leading players in the diabetes market 16 Chapter 1 Epidemiology analysis 18 Summary 18 Introduction 19 Disease description 19 Type 1 diabetes 19 Type 2 diabetes 21 Current and future prevalence of diabetes 22 Diagnosis 24 Fast-track review for diabetes drugs 25 Current and future treatment patterns 26 Insulin prescribing 27 TZD prescribing 28 Chapter 2 Global diabetes market analysis 32 Summary 32 Introduction 33 History of antidiabetic drugs 33 iv Current growth drivers 34 Insulins 35 TZDs 36 Combination therapies 37 Future growth drivers 39 Non-injected insulin 41 Inhaled insulins 42 Oral insulins 43 Insulin patches 44 Dual PPAR agonists 45 GLP-1 agonists and DPP IV inhibitors 46 GLP-1 agonists 46 DPP IV inhibitors 47 Amylinomimetic agents 48 Chapter 3 Insulin market analysis 51 Summary 51 Introduction 52 Insulin categories and sales 52 Company market share 54 Brand market share and sales 55 Human Insulins 58 Brand analysis 58 Humulin (human insulin) 58 NovoLin (human insulin) 60 Fast-acting human insulin analogs 61 Brand analysis 61 Humalog (insulin lispro) 61 NovoLog (insulin aspart) 63 Apidra (insulin glulisine) 64 Long-acting insulin analogs 66 Brand analysis 66 Lantus (insulin glargine) 66 Levemir (insulin detemir) 68 Chapter 4 Oral antidiabetic (OAD) market analysis 71 Summary 71 Introduction 72 v OAD categories and sales 72 Company market share 76 Sulfonylurea products 77 Brand market share and sales 77 Brand analysis 80 Amaryl (glimepriride) 81 Glucotrol XL (glipizide) 82 Biguanide products 83 Brand market share and sales 83 Brand analysis 86 Glucophage & Glucophage XR (metformin) 86 Combined sulfonylurea & biguanide products (and other combination therapies) 88 Sulfonylurea + biguanide single-pill combination drugs 90 Glucovance (glyburide + metformin) 90 TZD + other OAD single-pill combination therapies 92 Thiazolidinedione (TZD) products 93 Brand market share and sales 94 Brand analysis 97 Drug analysis 97 Actos (pioglitazone) 97 Avandia (rosiglitazone) 99 Avandamet (rosiglitazone + metformin) 100 Alpha glucosidase inhibitor (AGI) products 102 Brand market share and sales 102 Brand analysis 105 Precose/Glucobay (acarbose) 105 Basen (voglibose) 106 Glyset/Diastabol (miglitol) 107 Other OAD products (the prandial glucose regulators) 108 Brand market shares and sales 108 Brand analysis 110 Prandin/NovoNorm (repaglinide) 111 Starlix (nateglinide) 113 Chapter 5 Leading players in the diabetes market 117 Summary 117 Introduction 118 Eli Lilly 119 Therapeutic focus 119 Insulin market share 120 Marketed products 121 vi R&D pipeline 121 Exenatide (synthetic exendin-4) 122 Ruboxistaurin 123 Pulmonary insulin (AIR) 123 Oralin 124 LY-818 (naveglitazar) 124 Novo Nordisk 125 Therapeutic focus 125 Insulin market share 126 Marketed products 127 R&D pipeline 128 NovoMix 50 and 70 (NN1185): Injectable insulin formulations 128 AERx iDMS (NN1998): An inhaled insulin 129 Liraglutide (NN2211) 129 Sanofi-Aventis 131 Therapeutic focus 131 Insulin and OAD market shares 132 R&D pipeline 133 Exubera 134 DiaPep277 135 Takeda 135 Therapeutic focus 135 OAD market share 136 Marketed products 136 R&D pipeline 137 Actos/metformin combination 137 ATL-962 138 TAK-559 138 TAK-654 138 TAK-428 138 GlaxoSmithKline 139 Therapeutic focus 139 OAD market share 140 Marketed products 140 R&D pipeline 141 Avandaryl 141 Avandamet XR 142 HIM-2 142 677954 142 Bristol-Myers Squibb 143 Therapeutic focus 143 OAD market share 144 Marketed products 144 R&D pipeline 145 Muraglitazar 146 Basulin 146 Inhaled Insulin 147 Pfizer 148 vii Therapeutic focus 148 Marketed products 148 R&D pipeline 149 Exubera 149 Novartis 150 Therapeutic focus 150 Marketed products 150 R&D pipeline 150 LAF237 150 Merck KGaA 151 Therapeutic focus 151 Marketed products 151 R&D pipeline 152 Index 154 viii List of Figures Figure 1.1: Prevalence of obese and overweight adults in US, 1976-2000 23 Figure 1.2: Proportion of type 2 diabetics diagnosed, 2003 24 Figure 1.3: Management of type 2 diabetes by physician type, 2003 26 Figure 1.4: Proportion of drug treated type 2 diabetics treated with insulin in monotherapy or combination, 2003 27 Figure 2.5: Development timeline for antidiabetic drug classes, 1920-2004 33 Figure 2.6: Overview of diagnosis rates, treatment rates and insulin prescribing trends in six major markets, 2003 35 Figure 2.7: Approved combination therapies for type 2 diabetes, 2003 37 Figure 2.8: Positive and negative developments influencing the antidiabetics market, 2004 & forwards 40 Figure 2.9: Overview of the non-invasive insulin pipeline, 2004 42 Figure 3.10: Insulin brands by company and type, 2004 55 Figure 3.11: US/European* market share of leading insulins (%), 1999-2003 56 Figure 3.12: Humulin SWOT analysis 59 Figure 3.13: NovoLin SWOT analysis 60 Figure 3.14: Humalog SWOT analysis 62 Figure 3.15: NovoLog SWOT analysis 63 Figure 3.16: Apidra SWOT analysis 65 Figure 3.17: Lantus SWOT analysis 67 Figure 3.18: Levemir SWOT analysis 68 Figure 4.19: Sales of OAD categories in Europe* and US ($m), 2003 75 Figure 4.20: Global* market share of leading sulfonylureas (%), 1999-2003 78 Figure 4.21: Amaryl SWOT analysis 81 Figure 4.22: Glucotrol XL SWOT analysis 82 Figure 4.23: Global* market share of leading biguanides, 1999-2003 84 Figure 4.24: Glucophage XR SWOT analysis 88 Figure 4.25: Glucovance SWOT analysis 91 Figure 4.26: US/European* market share of leading TZDs (%), 1999-2003 95 Figure 4.27: Actos SWOT analysis 98 Figure 4.28: Avandia SWOT analysis 100 Figure 4.29: Avandamet SWOT analysis 101 Figure 4.30: US/European* market share of leading AGIs (%), 1999-2003 103 Figure 4.31: Precose/Glucobay SWOT analysis 106 Figure 4.32: Basen SWOT analysis 107 Figure 4.33: US/European* market share of leading PGRs (%), 1999-2003 109 Figure 4.34: Prandin/NovoNorm SWOT analysis 112 Figure 4.35: Starlix SWOT analysis 113 Figure 5.36: Eli Lilly’s therapeutic focus, 2003-2010 119 Figure 5.37: Novo Nordisk’s therapeutic focus, 2003 and 2010 125 Figure 5.38: Sanofi-Aventis’ therapeutic focus, 2003 & 2010 131 Figure 5.39: Takeda’s therapeutic focus, 2003 & 2010 135 Figure 5.40: GSK’s therapeutic focus, 2003 & 2010 139 Figure 5.41: BMS’s changing therapeutic focus, 2003-2010 143 Figure 5.42: Pfizer’s changing therapeutic focus, 2003-10 148 Figure 5.43: Merck KGaA’s changing therapeutic focus, 2003 & 2010 151 ix List of Tables Table 1.1: Prevalence of Type 2 diabetes (m), 2003-2012 22 Table 1.2: US and European* Sales by Drug Class ($m), 2002-2003 29 Table 2.3: US/European* sales category totals ($m), 2002-2003 34 Table 3.4: US/European* Sales of insulins by category ($m), 2002-2003 53 Table 3.5: Insulin market share by company and territory (%), 2002-2003 54 Table 3.6: Sales of leading insulins by country ($m), 2002-2003 57 Table 3.7: Branded human insulins 58 Table 3.8: Branded fast-acting human insulin analogs 61 Table 3.9: Branded long-acting human insulin analogs 66 Table 4.10: Frequency and level of dose of OADs 73 Table 4.11: US/European* OAD category market share (%), 2002-2003 74 Table 4.12: US/European* OAD Market Share by Company (%), 2002-2003 76 Table 4.13: Sales of leading sulfonylureas by country ($m), 2002-2003 79 Table 4.14: Branded sulfonylureas 80 Table 4.15: Sales of leading biguanides by country ($m), 2002-2003 85 Table 4.16: Branded biguanides 86 Table 4.17: Proportion of patients receiving monotherapy versus combination therapy treatment (%), 2003 89 Table 4.18: US/European* sales of sulfonylurea + biguanide single-pills ($m), 1999-2003 90 Table 4.19: Sales of leading TZDs by country ($m), 2002-2003 96 Table 4.20: Branded TZDs 97 Table 4.21: Sales of leading AGIs by country ($m), 2002-2003 104 Table 4.22: Branded AGIs 105 Table 4.23: Sales of leading PGRs by country (%), 2002-2003 110 Table 4.24: Branded PGRs 111 Table 5.25: US/European* diabetes market share by company (%), 2002-2003 118 Table 5.26: US Insulin Market Share by Company (%), 2002-2003 120 Table 5.27: US/European* sales of Eli Lilly’s marketed diabetes portfolio ($m), 2002-2003 121 Table 5.28: Projected sales of Eli Lilly’s diabetes R&D pipeline ($m), 2007 & 2010 122 Table 5.29: European* insulin market share by company (%), 2002-2003 126 Table 5.30: US/European* sales of Novo Nordisk’s marketed diabetes portfolio ($m), 2002-2003 127 Table 5.31: Projected sales of Novo Nordisk’s diabetes R&D pipeline ($m), 2007 & 2010 128 Table 5.32: US/European* sales of Sanofi-Aventis’ marketed diabetes portfolio ($m), 2002-2003 133 Table 5.33: Projected sales of Sanofi-Aventis’ diabetes R&D pipeline ($m), 2003 & 2010 133 Table 5.34: US/European* sales of Takeda’s marketed diabetes portfolio ($m), 2002-2003 136 Table 5.35: Projected sales of Takeda’s diabetes R&D pipeline ($m), 2007 & 2010 137 Table 5.36: US/European* sales of GSK’s marketed diabetes portfolio, 2002-2003 140 Table 5.37: GSK’s diabetes R&D pipeline, 2003 141 Table 5.38: US OAD Market Share by Company (%), 2002-2003 144 Table 5.39: US/European* sales of BMS’s diabetes portfolio, 2002-2003 145 Table 5.40: Projected sales of BMS’s diabetes R&D pipeline ($m), 2007 & 2010 145 Table 5.41: Projected sales of Merck KGaA’s diabetes R&D pipeline ($m), 2007 & 2010 152 AbstractBusiness Insights have teamed up with IMS Health to bring you, 'The Diabetes Market Outlook: Market analysis of future growth and leading players by sector' This unique product offering provides an analysis of changing market conditions and strategic future outlook using the gold standard IMS Health sales data, an unrivalled source of pharmaceutical intelligence on the diabetes market. This report analyzes diabetes market dynamics and provides a country-by-country drug and brand analysis enabling you to assess product success/failure within US and European geographical markets. This report focuses on the market segmentation of key anti-diabetic drugs (insulin and oral anti-diabetic (OAD)), and also reviews the growth strategies of leading players in the diabetics market. Upcoming revolutionary products in development are also investigated, highlighting those expected to drive market growth in the future and transform the treatment options for diabetic patients. Diabetes type 2 has now reached epidemic levels, affecting over 30 million people in the US and Europe, with this figure projected to rise to over 40 million by 2012. Rising rates of obesity and the increasing age demographic are key drivers of this epidemic. Ensure you maximize the opportunities presented by this demographic growth, drive product development and exploit new and existing revenue streams in this rapidly growing market.Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||